Combined intravenous and intra-arterial cyclophosphamide, doxorubicin, and cisplatin (CICSA) in the management of select patients with invasive urothelial tumors

C. J. Logothetis, M. L. Samuels, D. E. Selig, S. Wallace, D. E. Johnson

Research output: Contribution to journalArticlepeer-review

21 Scopus citations

Abstract

Twenty-eight patients with unresectable urothelial tumors who had no evidence of distant visceral metastasis were managed with iv CISCA (cyclophosphamide, doxorubicin, and cisplatin) and intra-arterial (ia) CISCA chemotherapy. Ten patients had locally advanced disease only and 18 had locally advanced disease with nodal metastasis (ten in pelvic nodes; seven in pelvic and para-aortic nodes; and one in pelvic, para-aortic, and mesenteric nodes). Eleven patients (39%) achieved a complete remission, with a median duration of 49 weeks (range, 25-108). Seven patients (25%) achieved an objective response and ten patients (36%) failed to respond. Iv and ia CISCA chemotherapy is effective in the management of advanced urothelial tumors. Patients with locally advanced disease with or without the presence of nodal metastasis are a select population in whom frequent complete remissions can be achieved.

Original languageEnglish (US)
Pages (from-to)33-38
Number of pages6
JournalCancer Treatment Reports
Volume69
Issue number1
StatePublished - 1985

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Combined intravenous and intra-arterial cyclophosphamide, doxorubicin, and cisplatin (CICSA) in the management of select patients with invasive urothelial tumors'. Together they form a unique fingerprint.

Cite this